BioMedNewsBreaks — Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.”

To view the full article, visit https://ibn.fm/dG4JQ

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the…

1 day ago

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt:…

2 days ago

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ:…

3 days ago

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Acquires Zoolzy to Expand Pharmaceutical Supply Chain and Veterinary Market Reach

Earth Science Tech (OTC: ETST), a strategic holding company focused on a diversified portfolio, announced…

3 days ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing

Regentis Biomaterials (NYSE American: RGNT) is strengthening the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair…

4 days ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology

VERAXA Biotech (NASDAQ: VRXA) was featured in a recent article highlighting how its collaboration with AI-focused…

4 days ago